Company & Sponsor Intelligence
Bial - Portela C S.A.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials22
Recruiting0
Completed22
Countries7
Therapeutic footprint
epilepsyparkinsons
Indexed studies
NCT02171195A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093
epilepsy · United KingdomPHASE1
epilepsy · United KingdomPHASE1
NCT02287415The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin
epilepsy · PHASE1
epilepsy · PHASE1
NCT03095105Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects
parkinsons · GermanyPHASE1
parkinsons · GermanyPHASE1
NCT03116321Bioequivalence of Two Different Sources of Eslicarbazepine Acetate
epilepsy · PHASE1
epilepsy · PHASE1
NCT00957684Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures
epilepsy · PortugalPHASE3
epilepsy · PortugalPHASE3
NCT02305316Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone
parkinsons · PHASE1
parkinsons · PHASE1
NCT02777671Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers
epilepsy · PortugalPHASE1
epilepsy · PortugalPHASE1
NCT02283814A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate
epilepsy · PHASE1
epilepsy · PHASE1
NCT01519284Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic
parkinsons · PortugalPHASE1
parkinsons · PortugalPHASE1
NCT02071823Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules
parkinsons · CanadaPHASE1
parkinsons · CanadaPHASE1
NCT02172742The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin
epilepsy · PortugalPHASE1
epilepsy · PortugalPHASE1
NCT01879332A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers
epilepsy · United StatesPHASE1
epilepsy · United StatesPHASE1
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →